Conversely, our results reinforced the CHOICE (Choices for Healthy Outcomes in Caring for end-stage renal disease) study findings [19], which showed that CVC was associated with a significant state of inflammation (e.g., elevated CRP and interleukin 6) and higher mortality, supporting the classic recommendations and the current consensus regarding AVF as the first VA choice for HD [20,21]. This evidence concerns the gene CRP and chronic kidney disease.